Immunohitochemical Study Of P21WAF1 And P53 Proteins In Prostatic Neoplasia

Cancer prostate is the fourth most commonly diagnosed malignancy in men worldwide . The biology of early prostate cancer is variable and extends over many years, with some tumors progressing slowly and others progressing more rapidly. More precise markers are still needed to better clinically differentiate patients with more aggressive versus indolent prostate carcinoma (Claudio et al; 2002) The present study was a retrospective study of 50 cases of prostatic lesions and included 9 cases of benign prostatic hyperplastia, 7 premalignant and 34 cases of prostatic adenocarcinoma. The cases were selectively collected from the Pathology Department, Faculty of Medicine Zagazig University as well as from some private laboratories, during the period from January 1998 to December 2002, aiming at evaluating the role ofp21 WAFI/CtPI and p53 in benign, premalignant and malignant prostatic lesions.The age incidence of all prostatic lesions ranged from 40 -80 with the highest incidence above the 7th decade for premalignant lesions as well as prostatic adenocarcinoma, while the 6th decade was the highest incidence for the benign hyperplastic lesions. The study involved 22 radical prostatectomy specimens, 23 TUR specimens. and 15 TRUS biopsies.In this study, p21WAfI/CIPI and p53 expression were exclusively nuclear with faint cytoplasmic staining. p53 immunoexpression was absent in benignprostatic lesions, present mainly in high grade PIN intermingled with carcinoma and in poorly differentiated indicating an association with poor prognosis.